Orthocell Flags Strong U.S. Remplir Momentum As AGM Addresses Share Growth
OCC: $0.575 +3.60% · MC: $155M
At its AGM, Orthocell said October was its strongest month of U.S. Remplir sales since launch, with early November also showing encouraging momentum; the chair said sustaining the pace over the next six months could deliver a healthy top line at significant margins. The company reported FY2026 revenue growth of 45% and cash of approximately $39 million, while noting shareholder disappointment with recent share-price performance.

Comments